Innate and Adaptive
Immune Modulator

Innate and Adaptive
Immune Modulator

Innate and Adaptive
Immune Modulator

Odetiglucan

A Systemically Administered Innate and Adaptive Immune Modulator

Odetiglucan, our immune modulator therapeutic candidate, is systemically administered and has been observed to modulate both the innate and adaptive immune systems.

Odetiglucan is a pathogen-associated molecular pattern (PAMP) which is designed to enhance innate immune functions, including cytotoxic effector mechanisms, to reverse immunosuppression and facilitate cross-talk with the adaptive immune system. We have observed clinical benefits of odetiglucan as a monotherapy and in combination with multiple standard of care therapies in different tumor types.

Removing a Tumor’s Protective Shield

Tumors disrupt the structure and function of surrounding normal tissues, creating an immunosuppressive defense that is largely governed by local immune cells. This response protects the tumor from immune detection and attack, while supporting an immune suppressive microenvironment that further enables tumors to survive and grow.

Odetiglucan is an investigational immune modulator that has been observed to reprogram the tumor immune microenvironment by recruiting a unique set of co-receptors (Dectin-1, CR3, FcɣR) on immune cells, that collectively work to drive more effective tumor detection and destruction.

The Odetiglucan Immune Complex

In preclinical and clinical studies, we have observed that odetiglucan forms an immune complex by binding anti-beta glucan antibodies (ABA) and being opsonized with complement component 3.  Together, these agonize a unique combination of receptors on immune cells: Dectin-1 receptor, complement receptor 3 (CR3), and Fc Fragment of IgG Receptor IIa (FcγRIIA). In this fashion, the odetiglucan immune complex binds to immune cells in circulation, and activates innate and adaptive immunity at the site of the tumor without causing systemic toxicity that has been observed with other PRR agonists.

Clinical Development and
Strategy

In a Phase 2 clinical trial, odetiglucan was generally well-tolerated and demonstrated encouraging median overall survival (mOS), and disease control rates (DCR) in patients with metastatic triple-negative breast cancer (mTNBC). We are building on these clinical data via our Phase 2 study of odetiglucan in combination with pembrolizumab in metastatic breast cancer (mBC) patients who have failed hormone therapy +/- CDK4/6 inhibitors.

We are exploring additional clinical studies with odetiglucan, including a Phase 1b study of odetiglucan in combination with an agonistic CD40 antibody (CD40a) in pancreatic ductal adenocarcinoma (PDAC). Preclinically, we are exploring the monotherapy activity and mechanism we have defined for odetiglucan in liver metastasis.